Full text
Earnings transcript
Read the complete earnings call transcript.
SCL
Stepan Company
$52.4
0.97
(1.89%)
| Exchange: | NYSE |
| Market Cap: | 1.19B |
| Shares Outstanding: | 22.917M |
Delayed data
About The Company
| Sector: | Basic Materials | |||||
| Industry: | Chemicals – Specialty | |||||
| CEO: | Luis E. Rojo | |||||
| Full Time Employees: | 2396 | |||||
| Address: |
| |||||
| Website: | https://www.stepan.com |
Stepan Company, along with its various subsidiaries, specializes in the production and sale of both specialty and intermediate chemical compounds. These chemicals are supplied to other manufacturers for integration into a diverse range of finished goods. The company’s operations are divided into three primary business segments: Surfactants, Polymers, and Specialty Products. The Surfactants division focuses on surface-active agents, which are key ingredients in numerous consumer and industrial cleaning formulations, including detergents for laundry, dishes, carpets, and hard surfaces, as well as personal care items like shampoos and body washes. Beyond cleaning, these surfactants are utilized in fabric softeners, germicidal quaternary compounds, disinfectants, and as lubricating components. Their applications also extend to agricultural emulsifiers and various industrial processes involving latex systems, plastics, and composites. The Polymers segment manufactures polyurethane polyols, critical for producing rigid foam used in thermal insulation within the construction sector. These polyols also act as foundational raw materials for coatings, adhesives, sealants, and elastomers (collectively known as CASE applications). This division further supplies both liquid and powdered polyester resins, which are also employed in CASE products. Additionally, it produces phthalic anhydride, an essential component in unsaturated polyester resins, alkyd resins, and plasticizers found in building materials, automotive parts, marine vessels, and other consumer items. Finally, the Specialty Products segment provides flavors, emulsifiers, and solubilizers specifically designed for incorporation into food, flavoring systems, nutritional supplements, and pharmaceutical applications. Stepan Company’s market reach is international, with operations spanning the United States, France, Poland, the United Kingdom, Brazil, Mexico, and other global territories. The company was established in 1932 and is headquartered in Northbrook, Illinois.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 2,325,768 | 2,180,274 | 2,332,114 |
| Gross Profit | 277,598 | 272,214 | 269,888 |
| EBITDA | 169,675 | 192,101 | 212,174 |
| Operating Income | 58,613 | 70,480 | 69,382 |
| Net Income | 40,204 | 50,370 | 46,895 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 2,363,354 | 2,304,648 | 2,357,702 |
| Total Liabilities | 1,146,864 | 1,134,714 | 1,113,692 |
| Total Stockholders Equity | 1,216,490 | 1,169,934 | 1,244,010 |
| Total Debt | 712,172 | 682,831 | 340,975 |
| Cash and Cash Equivalents | 129,823 | 99,665 | 0 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 174,876 | 162,053 | 147,882 |
| Capital Expenditure | -260,335 | -122,776 | 0 |
| Free Cash Flow | -85,459 | 39,277 | 147,882 |
| Net Income | 40,204 | 50,370 | 46,895 |
| Net Change in Cash | -43,927 | -30,158 | 33,023 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2028 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,718,806.186 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 2,756,793.813 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 2,737,800 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 257,423.225 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 261,019.987 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 259,221.606 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 168,388.763 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 170,741.519 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 169,565.141 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 0 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 0 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 1 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 0 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Solid Financial Performance: Stepan Company reported a 9% growth in adjusted EBITDA for Q3 2025, as highlighted in the earnings call transcript, reflecting strong operational efficiency and profitability improvements despite market challenges.
- Positive Revenue Trends: Historical income statement data indicates consistent revenue generation, supported by diversified product categories as seen in revenue product segments, which likely contributes to financial stability.
- Strong Liquidity Position: Balance sheet metrics, including cash and cash equivalents and a favorable current ratio (TTM), suggest the company maintains adequate liquidity to meet short-term obligations, providing a buffer against operational risks.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates SCL intrinsic value between $25.20 – $53.85 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about SCL valuation
Is Stepan Company (SCL) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Stepan Company (SCL) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is SCL a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SCL trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is SCL’s P/E ratio?
You can see SCL’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for SCL?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is SCL a good long-term investment?
Whether SCL fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
SCL
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.89
Trading Metrics:
| Open: | 52.13 | Previous Close: | 51.43 | |
| Day Low: | 51.79 | Day High: | 53.29 | |
| Year Low: | 41.82 | Year High: | 68 | |
| Price Avg 50: | 51.25 | Price Avg 200: | 49.91 | |
| Volume: | 123190 | Average Volume: | 145511 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeSCL full analysis
Welcome to MARKETSNAP’s SWOT analysis for Stepan Company, also known by its ticker SCL. If you’re not familiar with Stepan Company, let me give you the quick rundown. This is a specialty chemical manufacturer operating in the Materials sector, specifically within the chemicals industry. They produce a wide range of surfactants, polymers, and specialty ingredients used in everything from personal care products to industrial applications. With a global footprint and a solid workforce, they’ve carved out a niche in a…
